Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

UC San Diego scientists discover enzyme responsible for scrambling cancer genomes; results could enable new treatments for ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

A sprawling international fertility scandal is forcing regulators and doctors across Europe to rethink donor screening after ...

Fact checked by Nick Blackmer A new survey of 100 centenarians found six simple weekly habits they do to stay healthy.These ...

Researchers found that both how often and how much someone drinks significantly shape their cancer risk, even at moderate ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...

The donor, who was not identified, was paid to donate as a student beginning in 2005, according to the report.

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the long-term health effects ...